Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
Phase of Trial: Phase IV
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd; Eisai Inc
- 08 Mar 2019 Planned End Date changed from 8 Nov 2019 to 1 Aug 2020.
- 08 Mar 2019 Planned primary completion date changed from 19 May 2019 to 1 Feb 2020.
- 22 Jun 2018 New trial record